GlaxoSmithKline plc Company Profile (LON:GSK)

About GlaxoSmithKline plc

GlaxoSmithKline plc logoGlaxoSmithKline plc (GSK) is a healthcare company. The Company is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. The Company's segments include Pharmaceuticals, Pharmaceuticals R&D, Vaccines and Consumer Healthcare. The Pharmaceuticals business develops and makes medicines to treat a range of acute and chronic diseases. The Vaccines business develops, produces and distributes over 1.9 million vaccines every day to people across the world. The Consumer Healthcare business develops and markets products in various categories, such as Wellness, Oral health, Nutrition and Skin health. The Pharmaceuticals Research and Development (R&D) focuses on the discovery and development in various areas of research, which include human immunodeficiency virus (HIV) and infectious diseases, oncology, immuno-inflammation, respiratory and rare diseases.

Industry, Sector and Symbol:
  • Sector: N/A
  • Industry: N/A
  • Sub-Industry: N/A
  • Exchange: LON
  • Symbol: GSK
  • CUSIP:
Key Metrics:
  • Previous Close: $21.57
  • 50 Day Moving Average: $1652.33
  • 200 Day Moving Average: $1532.89
  • 52-Week Range: £48,610,000 - GBX 1,227.50
  • Trailing P/E Ratio: 2753.92
  • P/E Growth: 0.00
  • Market Cap: $80.32B
  • Outstanding Shares: 4,861,000,000
Additional Links:

Analyst Ratings

Consensus Ratings for GlaxoSmithKline plc (LON:GSK) (?)
Ratings Breakdown: 3 Sell Ratings, 16 Hold Ratings, 8 Buy Ratings
Consensus Rating:Hold (Score: 2.19)
Consensus Price Target: GBX 1,676.44

Analysts' Ratings History for GlaxoSmithKline plc (LON:GSK)
Show:
DateFirmActionRatingPrice TargetDetails
9/23/2016Citigroup Inc.Reiterated RatingBuyView Rating Details
9/22/2016JPMorgan Chase & Co.Reiterated RatingNeutralView Rating Details
9/20/2016Liberum CapitalReiterated RatingBuyGBX 1,900View Rating Details
9/20/2016Goldman Sachs Group Inc.Reiterated RatingBuyGBX 1,800View Rating Details
9/16/2016Beaufort SecuritiesReiterated RatingBuyView Rating Details
9/14/2016Societe GeneraleReiterated RatingSellGBX 1,320View Rating Details
9/14/2016BNP ParibasDowngradeUnderperformGBX 1,520View Rating Details
9/13/2016Jefferies GroupLower Price TargetBuyGBX 2,000 -> GBX 1,900View Rating Details
9/12/2016HSBCReiterated RatingBuyGBX 1,970View Rating Details
9/8/2016Deutsche Bank AGReiterated RatingHoldView Rating Details
9/5/2016Shore CapitalReiterated RatingHoldView Rating Details
8/9/2016Berenberg BankSet Price TargetNeutralGBX 1,885View Rating Details
8/4/2016Independent Research GmbHSet Price TargetNeutralGBX 1,800View Rating Details
7/28/2016Sanford C. BernsteinSet Price TargetNeutralGBX 1,755View Rating Details
7/28/2016Bryan, Garnier & CoReiterated RatingBuyView Rating Details
7/27/2016S&P Global Inc.Set Price TargetNeutralGBX 1,650View Rating Details
7/14/2016Credit Suisse Group AGReiterated RatingNeutralGBX 1,800View Rating Details
7/11/2016Morgan StanleyBoost Price TargetEqual weightGBX 1,500 -> GBX 1,650View Rating Details
7/7/2016Canaccord GenuityReiterated RatingHoldGBX 1,785View Rating Details
5/4/2016Barclays PLCBoost Price TargetOverweightGBX 1,650 -> GBX 1,670View Rating Details
3/10/2016AlphaValueReiterated RatingAddGBX 1,536View Rating Details
2/12/2016Baader BankReiterated RatingHoldGBX 1,530View Rating Details
1/28/2016Leerink SwannReiterated RatingMarket PerformGBX 1,565View Rating Details
1/13/2016NatixisReiterated RatingNeutralGBX 1,470View Rating Details
11/17/2015JP Morgan CazenoveReiterated RatingNeutralGBX 1,370View Rating Details
11/6/2015Oddo SecuritiesReiterated RatingReduceGBX 1,360View Rating Details
10/5/2015Kepler Capital MarketsReiterated RatingHoldGBX 1,540View Rating Details
9/7/2015Bank of America Corp.UpgradeNeutralView Rating Details
6/9/2015Cenkos Securities LtdReiterated RatingBuyGBX 1,643View Rating Details
5/7/2015Charles StanleyReiterated RatingaccumulateView Rating Details
(Data available from 9/26/2014 forward)

Earnings

Earnings History for GlaxoSmithKline plc (LON:GSK)
No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for GlaxoSmithKline plc (LON:GSK)
Current Year EPS Consensus Estimate: $96.53 EPS

Dividends

Dividend History for GlaxoSmithKline plc (LON:GSK)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
7/27/2016GBX 191.12%8/11/20168/11/201610/13/2016
4/27/2016GBX 191.28%5/12/20165/12/20167/14/2016
10/28/2015GBX 191.34%11/12/201511/12/20151/14/2016
10/28/2015GBX 201.34%2/18/20162/18/20164/14/2016
7/29/2015GBX 191.38%8/13/20158/13/201510/1/2015
5/6/2015GBX 191.25%5/14/20155/14/20157/9/2015
2/4/2015GBX 231.56%2/19/20152/19/20154/9/2015
10/22/2014GBX 191.37%11/6/201411/6/20141/8/2015
7/23/2014GBX 191.28%8/6/20148/6/201410/2/2014
4/30/2014GBX 191.17%5/14/20145/14/20147/10/2014
2/5/2014GBX 231.36%2/19/20142/19/20144/10/2014
10/23/2013GBX 191.15%11/13/201311/13/20131/9/2014
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading History for GlaxoSmithKline plc (LON:GSK)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/9/2016Witty,Sir Andrew PInsiderBuy8GBX 1,616£129.28
8/12/2016Slaoui,MoncefInsiderBuy28GBX 2,208£618.24
8/9/2016Dingemans,SimonInsiderBuy8GBX 1,680£134.40
7/27/2016Witty,Sir Andrew PInsiderSell10,000GBX 1,693£169,300
7/11/2016Witty,Sir Andrew PInsiderBuy7GBX 1,671£116.97
7/8/2016Slaoui,MoncefInsiderBuy4GBX 2,169GBX 8,676
7/1/2016Cartwright,StaceyInsiderBuy461GBX 1,559£7,186.99
6/9/2016Dingemans,SimonInsiderBuy9GBX 1,441£129.69
5/20/2016Slaoui,MoncefInsiderBuy14GBX 2,100£294
5/12/2016Slaoui,MoncefInsiderBuy24GBX 2,103£504.72
5/11/2016Witty,Sir Andrew PInsiderBuy8GBX 1,476£118.08
4/28/2016Witty,Sir Andrew PInsiderSell10,000GBX 1,475£147,500
4/14/2016Slaoui,MoncefInsiderBuy495GBX 2,156£10,672.20
3/31/2016Anderson,Sir RoyInsiderBuy511GBX 1,405£7,179.55
3/9/2016Witty,Sir Andrew PInsiderBuy9GBX 1,404£126.36
2/15/2016Dingemans,SimonInsiderSell39,987GBX 1,406£562,217.22
2/9/2016Witty,Sir Andrew PInsiderBuy9GBX 1,369£123.21
1/28/2016Dingemans,SimonInsiderBuy684GBX 1,381£9,446.04
1/14/2016Witty,Sir Andrew PInsiderBuy43GBX 1,369£588.67
1/12/2016Dingemans,SimonInsiderBuy9GBX 1,359£122.31
12/9/2015Dingemans,SimonInsiderBuy9GBX 1,325£119.25
11/10/2015Dingemans,SimonInsiderBuy9GBX 1,366£122.94
10/12/2015Dingemans,SimonInsiderBuy10GBX 1,307£130.70
10/1/2015Rohner,UrsInsiderBuy525GBX 1,251£6,567.75
9/10/2015Witty,Sir Andrew PInsiderBuy10GBX 1,318£131.80
8/12/2015Dingemans,SimonInsiderBuy8GBX 1,443£115.44
7/10/2015Witty,Sir Andrew PInsiderBuy9GBX 1,369£123.21
7/1/2015Wijers,HansInsiderBuy534GBX 13.45GBX 7,182.30
3/31/2015Sir Christopher GentInsiderBuy3,991GBX 1,566£62,499.06
3/9/2015Moncef SlaouiInsiderSell22,274GBX 1,544£343,910.56
2/18/2015Moncef SlaouiInsiderSell1,580GBX 1,553£24,537.40
2/13/2015Simon DingemansInsiderSell12,605GBX 1,543.12£194,510.28
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for GlaxoSmithKline plc (LON:GSK)
DateHeadline
forbes.com logoInteresting GSK Put And Call Options For November 4th (LON:GSK)
www.forbes.com - September 22 at 12:25 PM
uk.finance.yahoo.com logoWhat GlaxoSmithKline plc’s choice of CEO means for shareholders (LON:GSK)
uk.finance.yahoo.com - September 22 at 8:24 AM
investors.com logoGlaxoSmithKline's choice of new boss disappoints City (LON:GSK)
www.proactiveinvestors.com - September 21 at 3:32 PM
News IconLeading stocks in today’s market: GlaxoSmithKline plc (NYSE:GSK) (LON:GSK)
twincountynews.com - September 21 at 3:32 PM
wsj.com logo[$$] GlaxoSmithKline Names Emma Walmsley as Next Chief Executive (LON:GSK)
www.wsj.com - September 21 at 9:33 AM
bloomberg.com logoInside the 10-Year, $1 Billion Battle for the Next Critical Antibiotic (LON:GSK)
www.bloomberg.com - September 21 at 9:33 AM
uk.finance.yahoo.com logoIs Sinclair Pharma plc a better bet than GlaxoSmithKline plc? (LON:GSK)
uk.finance.yahoo.com - September 21 at 9:33 AM
wsj.com logo[$$] GlaxoSmithKline Names Emma Walmsley as Next CEO (LON:GSK)
www.wsj.com - September 20 at 10:26 AM
News IconGlaxoSmithKline plc (GSK) Given Buy Rating at Beaufort Securities ... - DailyQuint (LON:GSK)
dailyquint.com - September 19 at 5:25 PM
forbes.com logoInteresting GSK Put And Call Options For May 2017 (LON:GSK)
www.forbes.com - September 19 at 12:27 PM
News IconGSK sells anaesthesia portfolio to Aspen (LON:GSK)
www.biospectrumasia.com - September 19 at 9:54 AM
4-traders.com logoGlaxoSmithKline : GSK cuts vaccine price for refugees, bowing to pressure (LON:GSK)
www.4-traders.com - September 19 at 9:54 AM
4-traders.com logoGlaxoSmithKline : GSK closes UK factory due to flooding (LON:GSK)
www.4-traders.com - September 16 at 5:11 PM
News IconLiberum Capital Indicates Potential 17.87% Increase In Shares Of GlaxoSmithKline PLC (LON:GSK)
larampadinapoli.com - September 16 at 5:11 PM
marketexclusive.com logoGlaxoSmithKline plc (NYSE:GSK) (GSK), Johnson & Johnson (NYSE:JNJ) Submit Subcutaneous Sirukumab MAA To ... - Market Exclusive (LON:GSK)
marketexclusive.com - September 15 at 8:24 AM
4-traders.com logoGlaxoSmithKline : *RPT/EXANE CUTS GLAXOSMITHKLINE TO 'UNDERPERFORM' (NEUTRAL) (LON:GSK)
www.4-traders.com - September 14 at 5:25 PM
bloomberg.com logoGlaxo, Astra Lead U.K. Drugmakers to Seek Continued EU Access (LON:GSK)
www.bloomberg.com - September 14 at 9:34 AM
4-traders.com logoGlaxoSmithKline : U.N. panel challenges market-based approach to drug R&D (LON:GSK)
www.4-traders.com - September 14 at 9:34 AM
reuters.com logoFDA staff flags concerns about Pfizer's quit-smoking drug study (LON:GSK)
uk.reuters.com - September 12 at 10:05 AM
4-traders.com logoGlaxoSmithKline : EU regulatory submission for sirukumab in RA (LON:GSK)
www.4-traders.com - September 12 at 10:05 AM
nasdaq.com logoGSK Reports EU Regulatory Submission For Sirukumab In Rheumatoid Arthritis (LON:GSK)
www.nasdaq.com - September 12 at 10:05 AM
News IconGlaxoSmithKline Sells Anesthetics to Aspen Pharmacare for Up to $370 Million (LON:GSK)
www.biospace.com - September 12 at 10:05 AM
News IconUpdate on GlaxoSmithKline plc (NYSE:GSK) for the day (LON:GSK)
twincountynews.com - September 7 at 5:28 PM
publicnow.com logo‘Real world’ data shows 83 percent effectiveness for Bexsero® in infants in first year of UK national meningitis B immunisation programme (LON:GSK)
www.publicnow.com - September 5 at 9:47 AM
News IconIs GlaxoSmithKline plc(NYSE: GSK), a large market cap stock a ... - The Daily Leicester (LON:GSK)
thedailyleicester.com - September 2 at 5:14 PM
News IconA look at a High Market Cap Stock: GlaxoSmithKline plc, GSK – The ... - The Daily Leicester (LON:GSK)
thedailyleicester.com - September 1 at 8:14 AM
uk.finance.yahoo.com logoIs this the best healthcare stock money can buy after today’s update? (LON:GSK)
uk.finance.yahoo.com - September 1 at 8:14 AM
News IconGSK extends closure date for divestment from drinks business (LON:GSK)
www.worldstagegroup.com - August 30 at 5:24 PM
4-traders.com logoGlaxoSmithKline : Ahmed - GSK Has Full Confidence in the Nigerian Economy (LON:GSK)
www.4-traders.com - August 29 at 5:13 PM
News IconHC Stocks Newsbeat: GlaxoSmithKline plc (ADR) (GSK), ACADIA Pharmaceuticals Inc. (ACAD) - share market updates (press release) (LON:GSK)
sharemarketupdates.com - August 25 at 10:20 AM
capitalcube.com logoETF’s with exposure to GlaxoSmithKline Plc : August 24, 2016 (LON:GSK)
www.capitalcube.com - August 24 at 5:12 PM
News IconGlaxoSmithKline plc (NYSE:GSK) Upcoming Earnings: What matter for investors? - The Voice Registrar (LON:GSK)
voiceregistrar.com - August 23 at 5:28 PM
capitalcube.com logoGlaxoSmithKline Plc :GSK-GB: Earnings Analysis: Q2, 2016 By the Numbers : August 23, 2016 (LON:GSK)
www.capitalcube.com - August 23 at 9:42 AM
ft.com logo[$$] US doctors waste millions on branded medicines (LON:GSK)
www.ft.com - August 21 at 4:52 PM
News IconDrug Manufacturers – Major: GlaxoSmithKline plc (NYSE:GSK) Position of the day (LON:GSK)
twincountynews.com - August 19 at 5:18 PM
News IconEconomic Crunch Hit Nigeria’s Healthcare Sector As Quoted Profits Dips (LON:GSK)
naija247news.com - August 16 at 8:40 AM
4-traders.com logoGLAXOSMITHKLINE : ViiV Healthcare launches phase III programme evaluating a two-drug regimen combining dolutegravir and lamivudine for HIV-1 treatment (LON:GSK)
www.4-traders.com - August 16 at 8:40 AM
publicnow.com logoViiV starts PhIII Programme for dolutegravir & 3TC (LON:GSK)
www.publicnow.com - August 16 at 8:40 AM
publicnow.com logoViiV Healthcare launches phase III programme evaluating a two-drug regimen combining dolutegravir and lamivudine for HIV-1 treatment (LON:GSK)
www.publicnow.com - August 16 at 8:40 AM
ft.com logo[$$] Yield to temptation as bond incomes fall (LON:GSK)
www.ft.com - August 11 at 5:33 PM
News IconHC Stocks in Top Row: GlaxoSmithKline plc (ADR) (GSK), Horizon Pharma PLC (HZNP) - share market updates (press release) (LON:GSK)
sharemarketupdates.com - August 10 at 12:46 PM
marketexclusive.com logoGlaxoSmithKline Plc (NYSE:GSK) To Offer Warranty On Strimvelis For Bubble Boy Disease - Market Exclusive (LON:GSK)
marketexclusive.com - August 10 at 12:46 PM
News IconGSK Nigeria sells N23b drink business this month (LON:GSK)
thenationonlineng.net - August 9 at 9:40 PM
uk.finance.yahoo.com logoAre GlaxoSmithKline plc and GW Pharmaceuticals plc simply too expensive? (LON:GSK)
uk.finance.yahoo.com - August 9 at 4:06 PM
finance.yahoo.com logoGlaxoSmithKline's Dividend Health (LON:GSK)
finance.yahoo.com - August 9 at 4:06 PM
News IconHC Stocks Buzzer: GlaxoSmithKline plc (ADR) (NYSE:GSK), Opko Health Inc. (NYSE:OPK) - share market updates (press release) (LON:GSK)
sharemarketupdates.com - August 9 at 8:16 AM
sg.finance.yahoo.com logoAnalysis - Future of drug pricing: paying for benefits not per pill (LON:GSK)
sg.finance.yahoo.com - August 9 at 8:16 AM
streetupdates.com logoOverview of Analysts Suggestions: Teva Pharmaceutical Industries ... - Street Updates (LON:GSK)
www.streetupdates.com - August 8 at 5:30 PM
News IconToday's Top Gainers in the Market GlaxoSmithKline plc (NYSE:GSK ... - The Daily Leicester (LON:GSK)
thedailyleicester.com - August 6 at 8:12 AM
streetupdates.com logoNoteworthy Analysts Suggestions: Horizon Pharma plc (NASDAQ:HZNP) , GlaxoSmithKline PLC (NYSE:GSK) - Street Updates (LON:GSK)
www.streetupdates.com - August 3 at 5:39 PM

Social


Last Updated on 9/26/2016 by MarketBeat.com Staff